Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

About me

Team Berlin Team, Investment comittee, Life Sciences & Chemistry, Partner
at HTGF since 2021

CV

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2024

SRTD biotech

Oncology

SRTD biotech was founded in Jülich by Dr Bernd Hoffmann and Dr Heribert Bohlen. The aim of the biotech start-up is to develop highly efficient RNA-based drugs based on a …

To the complete profileof SRTD biotech
2022

smartbax

Life Sciences

smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …

To the complete profileof smartbax
2022

Kupando

Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to …

To the complete profileof Kupando
2022

faCellitate

R&D Tools

faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …

To the complete profileof faCellitate
2019

Lindis Blood Care

Patient Monitoring

Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …

To the complete profileof Lindis Blood Care
2019

mediaire

Imaging & Navigation

mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …

To the complete profileof mediaire
2018

miRdetect

In-Vitro Dx

miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …

To the complete profileof miRdetect

Guided to exit

12 of 500 Companies
2018

adivo

Exit
Agriculture, Agritech & Animal Health

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species. Antibody …

To the complete profileof adivo

Recent posts

Last update 2 days ago
Zum Artikel

News

28. February 2025

Successful exit for HTGF: Pacira BioSciences Acquires GQ Bio

Zum Artikel

Story

27. February 2025

Innovation, Investments, Impact: A Look Back at HTGF’s Biotech Year 2024

Zum Artikel

News

13. December 2024

Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®

Zum Artikel

News

14. November 2024

SRTD biotech secures seed financing: Side-effect freeRNA therapeutics active only in diseased cells

Zum Artikel

News

13. November 2024

mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth

Zum Artikel

Story

18. January 2024